Cart
sales@molnova.com
Alloferon 2
CAS No. 347884-62-2
Alloferon 2( ——— )
Catalog No. M39844 CAS No. 347884-62-2
Alloferon 2 is an antiviral and antitumoral peptide. Alloferon 2 can be isolated from the blood of the blow fly Calliphora vicina (Diptera).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAlloferon 2
-
NoteResearch use only, not for human use.
-
Brief DescriptionAlloferon 2 is an antiviral and antitumoral peptide. Alloferon 2 can be isolated from the blood of the blow fly Calliphora vicina (Diptera).
-
DescriptionAlloferon 2 is an antiviral and antitumoral peptide. Alloferon 2 can be isolated from the blood of the blow fly Calliphora vicina (Diptera).
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number347884-62-2
-
Formula Weight1128.2
-
Molecular FormulaC46H69N19O15
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Chernysh S, et al. Antiviral and antitumor peptides from insects. Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12628-32.?
molnova catalog
related products
-
NSC-60339
NSC-60339 is an inhibitor of efflux pump, and a substrate of AcrAB-TolC, is a polybasic terephthalic acid derivative studied as a potential cancer chemotherapeutic agent.
-
PODOPHYLLIN
PODOPHYLLIN
-
Ergosterol peroxide
Ergosterol peroxide is an inhibitor of osteoclast differentiation, which has antiviral, trypanocidal, antitumor, and antiangiogenic actions, it can stimulate Foxo3a activity by inhibiting pAKT and c-Myc and activating pro-apoptotic protein Puma and Bax to induce cancer cell death.
